GNGuy W. Neff

Guy W. Neff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guy W. Neff has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 621 Treatment of HCV Recurrence After Liver Transplant: A Review of Early Virologic Responses Using Telaprevir, A Single Center Experience of 24 Patients

    by Elizabeth Cece, Guy W. Neff, Erin S. Parkinson, Nyingi Kemmer, Brenna J. Evans, Michelle Blake, Kristina Barber, Teresa Potter, Andrew Silverman, Macnish B. Christian, et al.

  • Su1699 Hospitalization Trends of Spontaneous Bacterial Peritonitis Over the Past Decade

    by Guy W. Neff, Macnish B. Christian, Adam Gordon, Nyingi Kemmer, Erin S. Parkinson, Elizabeth Cece, Angel E. Alsina

  • Su1698 Hospitalizations Outcomes in Portal Hypertension Complications Treated With Rifaximin or Lactulose Therapy

    by Guy W. Neff, Macnish B. Christian, Erin S. Parkinson, Elizabeth Cece, Nyingi Kemmer, Angel E. Alsina, Adam Gordon

  • Su1703 Recurrence of Spontaneous Bacterial Peritonitis in the Setting of Antibiotic Prophylaxis While Managed on Rifaximin or Lactulose

    by Guy W. Neff, Macnish B. Christian, Erin S. Parkinson, Elizabeth Cece, Angel E. Alsina, Nyingi Kemmer, Adam Gordon

    • 1 March 2011
      • Vol. 20  (1) , 93-6

    Herpes simplex virus hepatitis - it's high time we consider empiric treatment.

    by Udayakumar Navaneethan, Elisha Lancaster, Preethi G K Venkatesh, Jiang Wang, Guy W Neff

    Fulminant hepatitis is an uncommon complication of herpes simplex virus infection. Patients at risk, in particular pregnant women and immunosuppressed patients presenting with fulminant liver failure, receiving delayed acyclovir intervention may lose significant liver parenchyma prompting the need for liver transplantation. The diagnosis is often not straight forward due to the lack of specific signs or symptoms, while many patients are diagnosed at autopsy. Although herpes simplex virus associated fulminant hepatic failure carries a high mortality risk, early intervention with acyclovir may prove to be life saving. In fact, acyclovir given in the early stages of fulminant hepatic failure may prevent mortality and avoid the need for liver transplantation. We report here two pregnant women with fulminant herpes simplex virus hepatitis in whom a difference of a few hours in the initiation of empirical treatment made a vast difference to their hospital stay. The above results demonstrate a significant impact to fulminant hepatic failure and should prompt clinicians to consider empiric acyclovir therapy for at risk patients.


  • Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: A case series

    by Guy Neff, Victoria Zacharias, Tiffany E. Kaiser, Amy Gaddis, Nyingi Kemmer

    Previous data have suggested that the nonsystemic antibiotic rifaximin may be effective for the treatment of Clostridium difficile infection (CDI). This single-center retrospective study evaluated the efficacy of rifaximin for the treatment of CDI refractory to standard treatments in patients who had received liver transplants. Among 205 patients who had received liver transplants between July 2001 and December 2007, 3 patients with a confirmed diagnosis of C. difficile experienced recurrent diarrhea even though they received standard therapy. Patient 1, a 56-year-old male, patient 2, a 62-year-old male, and patient 3, a 73-year-old female, developed CDIs 190, 318, and 2310 days after transplantation, respectively. All patients experienced symptom recurrences after oral metronidazole therapy (250 mg 3 times daily for either 14 or 28 days) and after oral vancomycin therapy (125 mg 4 times daily for 14 days). Long-term vancomycin treatment (ie, 28 days) was required for patients 1 and 2. Vancomycin was discontinued in patient 3 because of increased creatinine levels. Oral rifaximin (400 mg 3 times daily) was initiated immediately after discontinuation of vancomycin therapy. Within 36 to 48 hours of the initiation of rifaximin treatment, diarrheal symptoms were resolved in all patients. After completing a 28-day course of rifaximin, patient 1 remained symptom-free during 185 days of follow-up, and patient 2 remained symptom-free during 250 days of follow-up. Patient 3 reported no symptoms within 155 days after the completion of rifaximin treatment. These findings suggest that rifaximin may be effective for the treatment of recurrent CDI and may provide a therapeutic option for CDI in immunocompromised patients. Liver Transpl 16:960-963, 2010. © 2010 AASLD.


  • Open Access

    Review: Predicting the probable outcome of treatment in HCV patients

    by Udayakumar Navaneethan, Nyingi Kemmer, Guy W. Neff

    Hepatitis C virus (HCV) is a major cause of chronic liver disease infecting more than 170 million people worldwide. HCV produces a wide gamut of manifestations varying from mild self-limiting disease to cirrhosis and hepatocellular carcinoma. A variety of viral, environmental and host genetic factors contribute to the clinical spectrum of patients infected with HCV and influence response to interferon (IFN) therapy. Predicting the probable outcome of treatment in patients with HCV infection has always been a challenging task. Treatment of HCV by pegylated interferon (peg-IFN) plus ribavirin eradicates the virus in approximately 60% of patients — HCV genotype 1 (42—51% response rates) and genotypes 2 and 3 (76—84% response rates); however, a significant number of patients do not respond to therapy or relapse following discontinuation of treatment or have significant side effects that preclude further treatment. Accurately predicting the patients who will respond to therapy is becoming increasingly important, both from the point of patient care and also with respect to the healthcare cost as clinicians need to continue treatment in patients who will respond and stop treatment in patients who are unlikely to respond. Viral RNA measurements and genotyping are used to optimize treatment as a low viral load and nongenotype 1 is more likely to be associated with sustained virological response (SVR). Rapid virological response (RVR) defined by undetectable HCV RNA at 4 weeks of treatment is increasingly being recognized as a powerful tool for predicting treatment response. A variety of host factors including single nuclear polymorphisms (SNPs) of IFN response genes, insulin resistance, obesity, ethnicity, human leukocyte antigens and difference in T-cell immune response has been found to modulate the response to antiviral treatment. The presence of severe fibrosis/cirrhosis on pretreatment liver biopsy predicts a poor response to treatment. Recent studies on gene expression profiling and characterization of the liver and serum proteome provide options to accurately predict the outcome of patients infected with HCV in the future. Future studies on the factors that predict treatment response and tailoring treatment based on this is required if we are to conquer this disease.


  • W1874 Access to Liver Transplantation: Indirect Measures of Delayed Referral

    by Victoria C. Zacharias, Nyingi Kemmer, Tiffany E. Kaiser, Rosann Giesting, Dilynn Russell, Guy W. Neff

  • Open Access

    Managing chronic hepatitis C in the difficult‐to‐treat patient

    by Nyingi Kemmer, Guy W. Neff

    Patients with chronic hepatitis C virus (HCV) infection and disease-related complications – among them cirrhosis and liver failure – pose a particular management challenge. Some of these patients may fail to respond to current therapy (non-responders), and some are affected so severely that treatment puts them at an unacceptable risk for complications. Treatment with pegylated interferon (peg-IFN) plus ribavirin improves hepatic enzyme levels and eradicates the virus in ≈50% of patients; however, a significant number of patients do not respond to therapy or relapse following treatment discontinuation. Several viral, hepatic and patient-related factors influence response to IFN therapy; many of these factors cannot be modified to improve long-term outcomes. Identifying risk factors and measuring viral load early in the treatment can help to predict response to IFN therapy and determine the need to modify or discontinue treatment. Retreatment options for patients who have failed therapy are limited. Retreatment with peg-IFN has been successful in some patients who exhibit an inadequate response to conventional IFN treatment, particularly those who have relapsed. Consensus IFN, another option in treatment-resistant patients, has demonstrated efficacy in the retreatment of non-responders and relapsers. Although the optimal duration of retreatment and the benefits and safety of maintenance therapy have not been determined, an extended duration is likely needed. This article reviews the risk factors for HCV treatment resistance and discusses the assessment and management of difficult-to-treat patients.